Method | Evaluation | MCC | Q2 | Se | Sp | PPV | NPV | AUC |
---|---|---|---|---|---|---|---|---|
SEQ-NEIGHB | Â | 0.18 | 65.84 | 46.67 | 72.55 | 37.34 | 79.52 | 0.64 |
SEQ-FREQ | unseen-protein | 0.25 | 63.33 | 65.71 | 62.50 | 38.05 | 83.87 | 0.69 |
EASE | cross-validation | 0.24 | 70.99 | 42.40 | 81.01 | 43.91 | 80.05 | 0.68 |
EASE-AA | Â | 0.37 | 72.72 | 65.35 | 75.31 | 48.12 | 86.11 | 0.76 |
SEQ-NEIGHB | Â | 0.16 | 64.77 | 45.64 | 71.55 | 36.24 | 78.79 | 0.65 |
SEQ-FREQ | unseen-protein | 0.24 | 61.95 | 66.97 | 60.18 | 37.33 | 83.72 | 0.70 |
EASE | independent test | 0.22 | 69.28 | 43.58 | 78.38 | 41.66 | 79.68 | 0.69 |
EASE-AA | Â | 0.36 | 71.53 | 65.76 | 73.57 | 46.85 | 85.85 | 0.78 |